-
-
Fosun International Selected for “2024 Global Zhejiang Business ESG Classic 100”
2024-10-14
The “Pursuit of Excellence - 2024 Global Zhejiang Business ESG Conference” was held at the Zhejiang University School of Management, under the guidance of the Zhejiang Daily Press Group and organized by Zheshangmagazine and other partners. Fosun International was recognized in the “2024 Global Zhejiang Business ESG Classic 100” for its significant contributions and
-
-
Fosun International Ranks 33rd in the “China Top 500 Private Enterprises 2024”
2024-10-13
On the afternoon of 12 October, the Press Conference of China Top 500 Private Enterprises 2024 was held in Lanzhou. During the press conference, the All-China Federation of Industry and Commerce released the 2024 lists of "China Top 500 Private Enterprises,” "China Top 500 Private Manufacturing Enterprises" and "China Top 100 Private Service Enterpr
-
-
Fidelidade Fuels Innovation with the Launch of Protechting 7.0
2024-10-10
Fidelidade, Fosun, and Hospital da Luz Boost Innovation CultureThe new edition of this Open Innovation program, led by Fidelidade and Fosun, focuses on technological solutions related to Artificial Intelligence and Sustainability in the fields of insurance and healthcare.Lisbon, October 10, 2024 – TheFidelidade Group- in partnership w
-
-
Fidelidade Launches Impact Centre for Climate Change
2024-10-07
Committed to accelerating progress towards a sustainable and resilient futureLisbon, 7th October 2024 - Today, Fidelidade launched the ICCC - Impact Centre for Climate Change, a Knowledge Centre dedicated to the in-depth study of climate change, which aims to mitigate risks and propose effective adaptations to protect the planet, people and resourc
-
-
Fosun International: The Hidden Gem Ready to Shine – Co-CEO Chen Qiyu on Unlocking True Value for Investors
2024-10-07
Source: Global Banking & Finance Review (issue 66)Date: 7, October 2024Chinese multinational conglomerate Fosun International Limited is a global innovation-driven consumer group whose mission is “creating happier lives for families worldwide.” Since its inception in 1992, Fosun has accumulated profound technology and innovation capabilities and a significant indus
-
-
Fosun successfully concluded 2024 sustainability-linked syndicated loan through greenshoe, final facility size reaching USD888 million with 25 participating banks
2024-10-02Fosun
(2 October 2024, Hong Kong) Fosun International Limited (HKEX stock code: 00656, “FosunInternational”, “Fosun” or “the Company”) has successfully completed asustainability-linked syndicated loan amounting to USD888 million. The loan wasinitially launched earlier this year in May with first close of USD603 million,followed by Greenshoe accessions. The final size r
-
-
Fitch upgrades Fidelidade's rating
2024-09-29
The international rating agency has upgraded the insurer ratings to A+ and A in the long-term.Lisbon, September 27, 2024.The American rating agency Fitch announced today that it has upgraded Fidelidade’s ratings from A to A+ (IFS – Insurer Financial Strength) and from A- to A (IDR – Issuer Default Rating), maintaining a stable outlook. These are the highest Fitch
-
-
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-21
·HANSIZHUANG (serplulimab) is the world’s first anti-PD-1 mAb for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefit
-
-
Fosun Pharma announces NMPA approval for Daxxify®, Marking the license-in of the world’s first and only peptide-powered botulinum toxin product to Mainland China
2024-09-11
(September 10, 2024, Shanghai, China) On September 9, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK) announced that the Biologics License Application (“BLA”) for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark:达希斐®, English trademark: DAXXIFY®, hereina